Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases... Show more
LCTX is the ticker for Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company listed on the NYSE American exchange (and also traded on the Tel Aviv Stock Exchange). The company focuses on regenerative medicine, developing cell replacement therapies intended to restore or support cells that are absent or dysfunctional because of degenerative disease, aging, or traumatic injury. Investors follow Lineage because its pipeline addresses large, underserved markets in ophthalmology and neurology, and because its lead program is backed by one of the world's largest pharmaceutical companies.
Lineage Cell Therapeutics was incorporated in 1990 and was formerly known as BioTime, Inc.; it adopted its current name in August 2019, changing its ticker from BTX to LCTX. The company is headquartered in Carlsbad, California, and employs roughly 70–80 people.
At the center of Lineage's business model is its proprietary cell-based technology platform, AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering). Using directed differentiation protocols applied to established, well-characterized pluripotent cell lines, the company manufactures specialized human cells designed to resemble cells found naturally in the body. Because these therapies are allogeneic — meaning the cells come from a universal donor source rather than from the patient — they can be produced in advance and stored, potentially enabling "off-the-shelf" treatment.
Lineage's pipeline includes several programs across ophthalmology and neurology:
As a clinical-stage company, Lineage generates limited revenue, primarily from collaborations and grants rather than product sales. Its business model depends on advancing programs through clinical trials and securing partnerships, milestones, and royalty arrangements. The Roche/Genentech collaboration on OpRegen is the most significant of these partnerships, providing both validation and non-dilutive funding.
Lineage attracts investor attention primarily because of the scale of the medical problems its therapies target and the strength of its lead collaboration. Age-related macular degeneration and spinal cord injury represent large patient populations with limited treatment options, and a successful cell replacement therapy could address significant unmet medical needs.
The company's allogeneic, "off-the-shelf" approach is also a key differentiator. Unlike autologous cell therapies, which are manufactured from a patient's own cells, allogeneic products can be produced in batches and used across many patients, potentially reducing cost and improving scalability. Lineage's in-house manufacturing capabilities and its track record of producing clinical-grade cell lots are positioned as competitive advantages in a field where manufacturing expertise is a meaningful barrier to entry.
The Roche/Genentech partnership provides external validation of the platform and reduces some of the financial burden of advancing OpRegen, while leaving Lineage with a potential path to milestone payments and royalties. For investors, this combination of a differentiated technology platform, a broad pipeline, and a large pharmaceutical collaboration forms the core of Lineage's long-term investment thesis.
Investing in Lineage carries the risks typical of clinical-stage biotechnology. The company's therapies are still in clinical or preclinical development, and there is no guarantee that any program will demonstrate sufficient safety or efficacy to reach regulatory approval or commercialization.
Lineage's financial profile reflects its early stage: it has historically generated modest revenue and recorded net losses, meaning it may need to raise additional capital through equity offerings, partnerships, or debt, which could dilute existing shareholders. The company's fortunes are also closely tied to its collaboration with Roche and Genentech; changes to that partnership, or setbacks in the OpRegen program, could have a material impact.
Additional considerations include intense competition in regenerative medicine and ophthalmology, the regulatory complexity of cell-based therapies, and the clinical and manufacturing risks inherent in developing complex biologics. Investors should understand that these factors make Lineage a higher-risk, longer-horizon investment relative to more established companies.
For investors seeking to identify opportunities across thousands of stocks and ETFs, Tickeron's AI Screener offers an AI-powered discovery platform. The tool helps traders and investors screen for ideas using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. By applying these criteria, users can efficiently narrow a broad universe of securities to those matching their own investment strategies. Explore the AI Screener to streamline your research process.
Lineage Cell Therapeutics occupies a distinctive position in regenerative medicine, combining a proprietary allogeneic cell platform with a pipeline aimed at some of the most challenging diseases in ophthalmology and neurology. Its partnership with Roche and Genentech on OpRegen adds a level of validation and support that is relatively uncommon for a company of its size. At the same time, Lineage remains a clinical-stage enterprise with limited revenue and the substantial risks that accompany drug development. For investors, the company represents a long-horizon opportunity tied to the success of its clinical programs and the broader evolution of cell therapy.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions
Industry Biotechnology